Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castrationresistant prostate cancer: Results from PREVAIL

Julie Graff, G. Baciarello, A. J. Armstrong, C. S. Higano, P. Iversen, T. W. Flaig, D. Forer, T. Parli, D. Phung, B. Tombal, Tomasz (Tom) Beer, C. N. Sternberg

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background: Prostate cancer disproportionately affects older men. Because age affects treatment decisions, it is important to understand the efficacy and tolerability of therapies for advanced prostate cancer in elderly men. This analysis describes efficacy and safety outcomes in men aged ≥75 years who received enzalutamide, an androgen receptor inhibitor, in the phase III PREVAIL trial. Patients and methods: PREVAIL was a randomised, double-blind, multinational study of oral enzalutamide 160 mg/day (N = 872) versus placebo (N = 845) in chemotherapy-naive men with metastatic castration-resistant prostate cancer. Overall survival (OS) and radiographic progression-free survival (rPFS) were coprimary end points. Subgroup analysis of men aged ≥75 years (elderly) and men aged

Original languageEnglish (US)
Article numbermdv542
Pages (from-to)286-294
Number of pages9
JournalAnnals of Oncology
Volume27
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Prostatic Neoplasms
Safety
Drug Therapy
Castration
Androgen Receptors
Double-Blind Method
Disease-Free Survival
MDV 3100
Placebos
Survival
Therapeutics

Keywords

  • Elderly patients
  • Enzalutamide
  • Metastatic castration-resistant prostate cancer
  • PREVAIL trial

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castrationresistant prostate cancer : Results from PREVAIL. / Graff, Julie; Baciarello, G.; Armstrong, A. J.; Higano, C. S.; Iversen, P.; Flaig, T. W.; Forer, D.; Parli, T.; Phung, D.; Tombal, B.; Beer, Tomasz (Tom); Sternberg, C. N.

In: Annals of Oncology, Vol. 27, No. 2, mdv542, 01.02.2016, p. 286-294.

Research output: Contribution to journalArticle

Graff, J, Baciarello, G, Armstrong, AJ, Higano, CS, Iversen, P, Flaig, TW, Forer, D, Parli, T, Phung, D, Tombal, B, Beer, TT & Sternberg, CN 2016, 'Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castrationresistant prostate cancer: Results from PREVAIL', Annals of Oncology, vol. 27, no. 2, mdv542, pp. 286-294. https://doi.org/10.1093/annonc/mdv542
Graff, Julie ; Baciarello, G. ; Armstrong, A. J. ; Higano, C. S. ; Iversen, P. ; Flaig, T. W. ; Forer, D. ; Parli, T. ; Phung, D. ; Tombal, B. ; Beer, Tomasz (Tom) ; Sternberg, C. N. / Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castrationresistant prostate cancer : Results from PREVAIL. In: Annals of Oncology. 2016 ; Vol. 27, No. 2. pp. 286-294.
@article{1d481a629b1241cca4b5238652007119,
title = "Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castrationresistant prostate cancer: Results from PREVAIL",
abstract = "Background: Prostate cancer disproportionately affects older men. Because age affects treatment decisions, it is important to understand the efficacy and tolerability of therapies for advanced prostate cancer in elderly men. This analysis describes efficacy and safety outcomes in men aged ≥75 years who received enzalutamide, an androgen receptor inhibitor, in the phase III PREVAIL trial. Patients and methods: PREVAIL was a randomised, double-blind, multinational study of oral enzalutamide 160 mg/day (N = 872) versus placebo (N = 845) in chemotherapy-naive men with metastatic castration-resistant prostate cancer. Overall survival (OS) and radiographic progression-free survival (rPFS) were coprimary end points. Subgroup analysis of men aged ≥75 years (elderly) and men aged",
keywords = "Elderly patients, Enzalutamide, Metastatic castration-resistant prostate cancer, PREVAIL trial",
author = "Julie Graff and G. Baciarello and Armstrong, {A. J.} and Higano, {C. S.} and P. Iversen and Flaig, {T. W.} and D. Forer and T. Parli and D. Phung and B. Tombal and Beer, {Tomasz (Tom)} and Sternberg, {C. N.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1093/annonc/mdv542",
language = "English (US)",
volume = "27",
pages = "286--294",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castrationresistant prostate cancer

T2 - Results from PREVAIL

AU - Graff, Julie

AU - Baciarello, G.

AU - Armstrong, A. J.

AU - Higano, C. S.

AU - Iversen, P.

AU - Flaig, T. W.

AU - Forer, D.

AU - Parli, T.

AU - Phung, D.

AU - Tombal, B.

AU - Beer, Tomasz (Tom)

AU - Sternberg, C. N.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Background: Prostate cancer disproportionately affects older men. Because age affects treatment decisions, it is important to understand the efficacy and tolerability of therapies for advanced prostate cancer in elderly men. This analysis describes efficacy and safety outcomes in men aged ≥75 years who received enzalutamide, an androgen receptor inhibitor, in the phase III PREVAIL trial. Patients and methods: PREVAIL was a randomised, double-blind, multinational study of oral enzalutamide 160 mg/day (N = 872) versus placebo (N = 845) in chemotherapy-naive men with metastatic castration-resistant prostate cancer. Overall survival (OS) and radiographic progression-free survival (rPFS) were coprimary end points. Subgroup analysis of men aged ≥75 years (elderly) and men aged

AB - Background: Prostate cancer disproportionately affects older men. Because age affects treatment decisions, it is important to understand the efficacy and tolerability of therapies for advanced prostate cancer in elderly men. This analysis describes efficacy and safety outcomes in men aged ≥75 years who received enzalutamide, an androgen receptor inhibitor, in the phase III PREVAIL trial. Patients and methods: PREVAIL was a randomised, double-blind, multinational study of oral enzalutamide 160 mg/day (N = 872) versus placebo (N = 845) in chemotherapy-naive men with metastatic castration-resistant prostate cancer. Overall survival (OS) and radiographic progression-free survival (rPFS) were coprimary end points. Subgroup analysis of men aged ≥75 years (elderly) and men aged

KW - Elderly patients

KW - Enzalutamide

KW - Metastatic castration-resistant prostate cancer

KW - PREVAIL trial

UR - http://www.scopus.com/inward/record.url?scp=84961642741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961642741&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdv542

DO - 10.1093/annonc/mdv542

M3 - Article

C2 - 26578735

AN - SCOPUS:84961642741

VL - 27

SP - 286

EP - 294

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 2

M1 - mdv542

ER -